Genetic susceptibility to hemorrhagic complications during warfarin therapy.
Tabrizi
A R
AR
Department of Surgery, Burn, Trauma, Surgical Critical Care Section, and the Molecular Diagnostic Laboratory, Washington University School of Medicine, St Louis, Mo.
Freeman
B D
BD
Buchman
T G
TG
Zehnbauer
B A
BA
D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects*; D001189:Aryl Hydrocarbon Hydroxylases; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D006470:Hemorrhage / Q000139:chemically induced* / Q000235:genetics*; D006801:Humans; D007866:Leg; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000235:genetics*; D014859:Warfarin / Q000009:adverse effects*
D000925:Anticoagulants; D014859:Warfarin; D003577:Cytochrome P-450 Enzyme System; D013250:Steroid Hydroxylases; D001189:Aryl Hydrocarbon Hydroxylases; D039181:Steroid 16-alpha-Hydroxylase